Cargando…

Peripheral PD-1 and Tim-3 percentages are associated with primary sites and pathological types of peritoneal neoplasms

PURPOSE: Programmed death-1 (PD-1) and T cell immunoglobulin and mucin-domain-containing molecule 3(Tim-3) may be used as the biomarkers for the therapy in patients with peritoneal neoplasms. In the current study, the differential percentages of peripheral PD-1 and Tim-3 are explored to investigate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Huihui, Zhao, Jin, Yuan, Judong, Zhang, Man
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052833/ https://www.ncbi.nlm.nih.gov/pubmed/36991376 http://dx.doi.org/10.1186/s12885-023-10752-2

Ejemplares similares

Different Expression Pattern of TIM-3 and Galectin-9 Molecules by Peripheral and Peritoneal Lymphocytes in Women with and without Endometriosis
por: Meggyes, Matyas, et al.
Publicado: (2020)

Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade
por: Tian, Tian, et al.
Publicado: (2021)

Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma
por: Zhang, Xingming, et al.
Publicado: (2019)

Altered expression of Tim family molecules and an imbalanced ratio of Tim-3 to Tim-1 expression in patients with type 1 diabetes
por: Liu, Yikai, et al.
Publicado: (2022)

Expression of PER, CRY, and TIM genes for the pathological features of colorectal cancer patients
por: Wang, Yong, et al.
Publicado: (2016)

Expression of Tim‐1 in primary CNS lymphoma
por: Kishimoto, Wataru, et al.
Publicado: (2016)

Elevation of Tim-3 and PD-1 Expression on T Cells Appears Early in HIV Infection, and Differential Tim-3 and PD-1 Expression Patterns Can Be Induced by Common γ-Chain Cytokines
por: Zhang, Zi-Ning, et al.
Publicado: (2015)

Immune Checkpoint Profiling in Humanized Breast Cancer Mice Revealed Cell-Specific LAG-3/PD-1/TIM-3 Co-Expression and Elevated PD-1/TIM-3 Secretion
por: Bruss, Christina, et al.
Publicado: (2023)

Tim-3 and PD-1 regulate CD8(+) T cell function to maintain early pregnancy in mice
por: XU, Yuan-Yuan, et al.
Publicado: (2017)

Altered expression of T cell Immunoglobulin-Mucin (Tim) molecules in peripheral blood mononuclear cells in aplastic anemia
por: Liu, Xin, et al.
Publicado: (2014)

Mast cell activation is enhanced by Tim1:Tim4 interaction but not by Tim-1 antibodies
por: Phong, Binh, et al.
Publicado: (2016)

The expression of apolipoproteina1 and its correlation with infiltration of urologic neoplasm
por: Hu, Huihui, et al.
Publicado: (2020)

Anti-fibrotic effect of decorin in peritoneal dialysis and PD-associated peritonitis
por: Jiang, Na, et al.
Publicado: (2020)

Enhanced upper genital tract pathologies by blocking Tim-3 and PD-L1 signaling pathways in mice intravaginally infected with Chlamydia muridarum
por: Peng, Bo, et al.
Publicado: (2011)

PD-1 and Tim-3 Pathways Regulate CD8(+) T Cells Function in Atherosclerosis
por: Qiu, Ming-Ke, et al.
Publicado: (2015)

PD‐1+ TIM‐3+ T cells in malignant ascites predict prognosis of gastrointestinal cancer
por: Nakano, Michitaka, et al.
Publicado: (2018)

Genetic polymorphisms of immune checkpoint proteins PD-1 and TIM-3 are associated with survival of patients with hepatitis B virus-related hepatocellular carcinoma
por: Li, Zhu, et al.
Publicado: (2016)

Role of the Peripheral Nervous System in PD Pathology, Diagnosis, and Treatment
por: Ma, Chengxiao, et al.
Publicado: (2021)

Tim Burton /
por: Marcos Arza, Marcos
Publicado: (2007)

Tim Lou
por: Lou, Hou Keong
Publicado: (2009)

Tim1 and Tim3 are not essential for experimental allergic asthma
por: Barlow, J L, et al.
Publicado: (2011)

A BIVALENT TIM-3/PD-1 BISPECIFIC ANTIBODY FOR THE TREATMENT OF PD-1 ANTIBODY RESISTANT OR REFRACTORY SOLID TUMORS
por: Luan, Yan, et al.
Publicado: (2023)

PD-L1 expression and immune cells infiltration in primary tracheobronchial neoplasm
por: Zheng, Kai-Fu, et al.
Publicado: (2021)

Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients
por: Limagne, Emeric, et al.
Publicado: (2019)

Prognostic Impact of PD-1 and Tim-3 Expression in Tumor Tissue in Stage I-III Colorectal Cancer
por: Kuai, Wentao, et al.
Publicado: (2020)

Different expression patterns of VISTA concurrent with PD-1, Tim-3, and TIGIT on T cell subsets in peripheral blood and bone marrow from patients with multiple myeloma
por: Huang, Shuxin, et al.
Publicado: (2022)

TIM-Finder: A new method for identifying TIM-barrel proteins
por: Si, Jing-Na, et al.
Publicado: (2009)

Mertk Interacts with Tim-4 to Enhance Tim-4-Mediated Efferocytosis
por: Moon, Byeongjin, et al.
Publicado: (2020)

An Emerging Role of TIM3 Expression on T Cells in Chronic Kidney Inflammation
por: Lu, Can, et al.
Publicado: (2022)

Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients
por: Marcq, Elly, et al.
Publicado: (2017)

The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma
por: Chen, Benjamin J., et al.
Publicado: (2019)

PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors
por: Wang, Jaeyun Jane, et al.
Publicado: (2019)

Interview with Tim Smith
por: Smith, Tim, et al.
Publicado: (2019)

Tim Berners-Lee
Publicado: (2004)

Come on, Sir Tim!
Publicado: (2009)

A novel germline HAVCR2 (TIM-3) compound heterozygous mutation is related to hemophagocytic lymphohistiocytic syndrome in EBV-positive peripheral T-cell lymphoma (NOS) with down-regulated TIM-3 signaling
por: Zhang, Yang, et al.
Publicado: (2022)

Metastatic Neuroendocrine Neoplasms of Unknown Primary: Clues from Pathology Workup
por: Juhlin, Carl Christofer, et al.
Publicado: (2022)

Peripheral Blood TIM-3 Positive NK and CD8+ T Cells throughout Pregnancy: TIM-3/Galectin-9 Interaction and Its Possible Role during Pregnancy
por: Meggyes, Matyas, et al.
Publicado: (2014)

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
por: Sakuishi, Kaori, et al.
Publicado: (2011)

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
por: Sakuishi, Kaori, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_jrbd9ck5b573idjj8egl02sa7p